1. Home
  2. |Insights
  3. |Litigation Note: Crowell & Moring Secures IP Victory for Watson Pharmaceuticals (now Actavis)

Litigation Note: Crowell & Moring Secures IP Victory for Watson Pharmaceuticals (now Actavis)

Firm News | less than 1 min read | 04.15.13

Washington, D.C. – April 15, 2013: Crowell & Moring represented Watson Pharmaceuticals, Inc. (now Actavis, Inc.) in successfully defending the patent infringement case brought by Bayer HealthCare Pharmaceuticals Inc. regarding its RE37,564 patent for the Yaz ® contraceptive. Today, the Federal Circuit reversed the adverse summary judgment decision made by the district court in March 2012 and held that Bayer's asserted patent claims were invalid. The court found that the cited prior art references set forth every limitation required by the asserted claims and provide express motivation to combine those teachings to derive the claimed oral contraceptive product. As a result of the decision today, Actavis has re-launched its generic product.


Insights

Firm News | 2 min read | 04.18.24

Global Public Affairs Executive Mark Elliot Joins Crowell & Moring International

Mark T. Elliot has joined Crowell & Moring International LLC (CMI) as senior director, bringing more than three decades of experience providing strategic public affairs, communications, government affairs and trade policy advice across a range of sectors and regions.